ライフサイエンスコーパス: placebo

1 development and progression of diabetic kidney disease than placebo.

2 ceived perindopril, 31 received bisoprolol, and 30 received placebo.

3 for the two primary end points than did those who received placebo.

4 se were more than 4 times as high with benralizumab as with placebo.

5 tion at 11 years of age compared with children treated with placebo.

6 hierarchical rules, the 50-mug patch was not compared with placebo.

7 study compared relapse rates in patients given SCIg versus placebo.

8 need for surgery and a greater improvement in symptoms than placebo.

9 coronary intervention were randomized to ranolazine versus placebo.

10 igned to receive treatment with perindopril, bisoprolol, or placebo (1:1:1) for the duration of trastuzumab adjuvant ther

11 g (2 puffs of 2.5 mug) or 2.5 mug (2 puffs of 1.25 mug), or placebo (2 puffs), administered through the Respimat device a

12 (at a dose of 20 mg or 40 mg, according to body weight) or placebo, administered subcutaneously every 2 weeks.

13 t cycles) were randomly assigned one to one to lapatinib or placebo after completion of first-line/initial chemotherapy f

14 rone receptor, beta-catenin, or vimentin expression between placebo and R-ketorolac treatment groups.

15 Three deaths occurred (2 hydroxyurea, 1 placebo, and none from malaria).

16 eive either oral lenalidomide (2.5 mg/day) or matching oral placebo capsules (2.5 mg/day) for 28-day cycles, until diseas

17 major depressive disorder were randomly assigned to open or placebo-controlled citalopram treatment.

18 magnetic resonance imaging (fMRI) in a 2-drug, double-blind placebo-controlled crossover design conducted from January 21

19 (n = 221) had peanut sensitivity and positive double-blind, placebo-controlled food challenges to an eliciting dose of 30

20 ng dose cohorts underwent a further double-blind crossover, placebo-controlled oral gluten challenge, which had a fixed s

21 To this end, we combined double-blind, placebo-controlled pharmacology [D2 receptor (D2R) antagonist

22 In this multicenter, double-blind, randomized, placebo-controlled study, 74 participants with peanut allergy

23 ve-week, phase III, randomized, double-masked, multicenter, placebo-controlled study.

24 METHOD: This 6-week, randomized, double-blind, placebo-controlled trial included patients with schizophrenia

25 Patients and Methods In this double-blinded, placebo-controlled trial, patients with HER2-positive early b

26 e same as those found in all four much smaller, randomized, placebo-controlled trials specifically designed to evaluate s

27 In this 12-week, double-blind, placebo-controlled, parallel-group trial, 401 participants ag

28 We did a multicentre, randomised, placebo-controlled, phase 3 trial (TACE 2) in 20 hospitals in

29 Multicenter, placebo-controlled, randomized trial (July 2013 to final foll

30 arker of mast-cell activation, to a greater extent than did placebo (decrease of 2.02+/-2.32 vs. 0.56+/-1.39 ng per milli

31 ipants who received rifampicin versus 71 (18%) who received placebo experienced treatment failure or disease recurrence,

32 3 or 30 mg once daily or 1, 3, 10, or 30 mg twice daily) or placebo for 4 weeks.

33 tear breakup time and ocular bulbar redness, compared with placebo, for both forms of omega-3 EFAs.

34 ) in the canakinumab-treated group (n = 5 of 7) than in the placebo group (n = 0 of 13).

35 ificantly more common in the canakinumab groups than in the placebo group.

36 a mean increase in quality of life score compared with the placebo group.

37 Vitamin D and placebo groups did not differ in change in insulin sensitivit

38 with genital infections was greater with empagliflozin than placebo in all subgroups by UACR status.

39 patients receiving immediate treatment and those receiving placebo in the deferred treatment group.

40 t trunk fat (decrease of 3.8%) compared with children given placebo (increase of 0.5%, increase of 0.05%, and decrease of

41 To determine if testosterone treatment compared with placebo is associated with improved verbal memory and other c

42 nts with peanut allergy (ages 4-25 years) were treated with placebo (n = 25), Viaskin Peanut 100 mug (VP100; n = 24) or V

43 of early AKI to receive intra-aortic MSCs (AC607; n=67) or placebo (n=68).

44 After birth, patients were randomly assigned to receive placebo or hydrocortisone (0.5 mg/kg twice per day for 7 days

45 wing statistical significance of the study drug compared to placebo ( P < 0.0161 and P < 0.0001, respectively).

46 receive second-line oral buparlisib (100 mg once daily) or placebo, plus intravenous paclitaxel (80 mg/m(2) on days 1, 8

47 ension week 96 (0.65, 0.56 to 0.75) remained lower than the placebo rate in TRAFFIC and TRANSPORT.

48 comparing the genetic sequence of viruses from vaccine and placebo recipients to the sequence of the vaccine itself, a t

49 sing an interactive voice-response system to eltrombopag or placebo, stratified by baseline platelet count (<10 x 10(9) p

50 sis and ascites to rifaximin 550 mg twice a day (n = 36) or placebo twice a day (n = 18).